¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷) : 2024-04-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷) : 2024-04-14
±³À°ÀÏÀÚ : 2024-04-14
±³À°Àå¼Ò : »ïÁ¤È£ÅÚ ¶óº¥´õȦ

±³À°ÁÖÁ¦ : ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑÆÄŲ½¼º´¹×ÀÌ»ó¿îµ¿ÁúȯÇÐȸ
´ã´çÀÚ : Ãֹ̼Ò
¿¬¶ôó : 02-6395-2876  

À̸ÞÀÏ : movement@kmds.or.kr

±³À°Á¾·ù : ½Å°æ°ú

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 50ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í »çÀüµî·Ï(Á¤È¸¿ø 50,000¿ø, ÁØȸ¿ø 30,000¿ø, ºñȸ¿ø Àü¹®ÀÇ 100,000¿ø, ºñȸ¿ø Àü°øÀÇ 40,000¿ø) ÇöÀåµî·Ï(Á¤È¸¿ø 60,000¿ø, ÁØȸ¿ø 40,000¿ø, ºñȸ¿ø Àü¹®ÀÇ 120,000¿ø, ºñȸ¿ø Àü°øÀÇ 50,000¿ø)


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 09:00~10:40 Session 1. Diagnosis and Management of Miscellaneous Movement Disorders °­¼®À±(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 09:00~09:30 Movement Disorders in In-patient & Emergency Settings ¹Úµ¿±Ô(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 09:30~10:00 Diagnosis and Management of Tardive Syndromes ¹é°æ¿ø(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:00~10:30 Functional Movement Disorders ¹ÚÁ¤ÀÌ(µ¿±¹ÀÇ´ë)

Åä·Ð 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:30~10:40 Q&A °­¼®À±(ÇѸ²ÀÇ´ë)

±âŸ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:50~12:10 Session 2. Lessons from Historic Clinical Trials ¹ÚÁ¤È£(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:50~11:30 Levodopa and Dopamine Agonists À¯´Þ¶ó(°æÈñÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 11:30~12:10 MAO-B Inhibitors and COMT Inhibitors Á¤¼®Á¾(¿¬¼¼ÀÇ´ë)

±âŸ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 12:10~13:00 Session 3. Case-based Learning - Panels Discussion Á¶¼º¾ç(¿ï»êÀÇ´ë)

Åä·Ð 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 12:10~13:00 How to Optimize the Dopaminergic Treatment of Parkinson¡¯s Disease? °í¼º¹ü/¹ÚÁ¤È£/À¯´Þ¶ó/Á¤¼®Á¾(°í·ÁÀÇ´ë/¼øõÇâÀÇ´ë/°æÈñÀÇ´ë/¿¬¼¼ÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷) : 2024-04-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ)2024³â Á¦8Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ ¼ö¸é´Ù¿ø°Ë»ç ±âº»±³À°°­Á : 2024-04-14
´ÙÀ½±Û ´ëÇѾ๰¿µ¾çÀÇÇÐȸ 2024³â ±¤ÁÖÇмú´ëȸ : 2024-04-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20664 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ)¼Ò¾Æû¼Ò³â°ú Çù·ÂÀÇ»ç Áý´ãȸ : 2024-05-28 0 14 2024-05-10
20663 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ Á¦1ȸ ÃÊÀ½ÆÄ ½ÇÀü ¾ÆÄ«µ¥¹Ì : 2024-05-27 0 5 2024-05-10
20662 ¼­¿ï ´ëÇѿ°èÁٱ⼼Æ÷Àç»ýÀÇÇÐȸ - Á¦20ȸ Ãá°èÇмú´ëȸ (ÇÏÀ̺긮µå) : 2024-05-26 0 5 2024-05-10
20661 ºÎ»ê ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ºÎ¿ï°æÁöȸ 5¿ù ¿¬¼ö°­Á : 2024-05-26 0 3 2024-05-10
20660 ¼­¿ï ´ëÇѽŰæ±Ù°ñ°áÃÊÀ½ÆÄÇÐȸ Á¦1ȸ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-05-25 0 7 2024-05-10
20659 ´ëÀü ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ½ÉÆ÷Áö¾ö-´ëÀüÃæ³² : 2024-05-25 0 0 2024-05-10
20658 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-25 0 1 2024-05-10
20657 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø The 1st International Symposium on Precision Oncology in Breast Cancer : 2024-05-25 0 11 2024-05-10
20656 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦1Â÷ FLS ÄÚµð³×ÀÌÅÍ ¿öÅ©¼ó : 2024-05-24 0 8 2024-05-10
20655 ¼­¿ï Á¦ 66ȸ Çѱ¹Ç×°ø¿ìÁÖÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-24 0 4 2024-05-10
20654 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-05-24 0 1 2024-05-10
20653 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24 0 1 2024-05-10
20652 ¼­¿ï Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ : 2024-05-24 0 4 2024-05-10
20651 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚµÈ ÀÌ°ú Áúȯ : 2024-05-23 0 5 2024-05-10
20650 °æ±â Çϳ²½ÃÀÇ»çȸ¿¬¼ö°­ÁÂ(¸¸¼º±âħ, ºÒ¸éÁõ) : 2024-05-23 0 0 2024-05-10
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷